Interpreting the Data with Tirzepatide
In an interview with CMHC co-chair Dr. Anne Peters, Juan Frías, MD, shared his thoughts about the data with tirzepatide across key phase 3 trials, and the potential role of this agent in the management of patients with type 2 diabetes, as well as in the management of obesity (recorded October 21, 2022).
▶︎
Navigating GLP-1 agonists | DoM Grand Rounds | 17 January 2024
▶︎
Drugs for Obesity, A Review of Semaglutide and Tirzepatide
▶︎
Top Five Peptides Dr Edwin Lee
▶︎
AHA 24 Late-Breaking Discussion: SUMMIT: Tirzepatide in Patients with HFpEF and Obesity
▶︎
Mounjaro (tirzepatide)... How does it work?
▶︎
Katie Couric discusses "celebrity weight loss drug," Ozempic with obesity expert and Dr. Lou Aronne
▶︎
Hit a Weight Loss Plateau on GLP-1s? Doctor Explains Your Options
▶︎
150: Why Tirzepatide Works Better Than GLP-1 Alone
▶︎
#Tirzepatide - First in a new class of #diabetes medication (Part 1)
▶︎
Tirzepatide + Metabolic Health: What the Latest Study Really Shows | Solo EP. 207
▶︎
Mastering GLP1 Agonists: What is microdosing? Dosing schedule, benefits, and more
▶︎
Anti-Obesity Pharmacotherapy for Long-Term Obesity Management | Carolyn T. Bramante, MD, MPH
▶︎
Lifestyle Medicine as a Clinical Tool for Type 2 Diabetes Remission
▶︎
2023 Tirzepatide Lecture: Dr. Heidi Diez, PharmD, MCT2D Co-Director
▶︎
GLP 1, Mounjaro, Wegovy & Ozempic: How These Affect Weight Loss & Metabolic Health | Dr. Rob Lustig
▶︎
How Do Ozempic, Mounjaro & Other GPL-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman
▶︎
Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity
▶︎
10 GLP 1 Mistakes That Are Ruining Your Weight Loss
▶︎
TIRZEPATIDE (MOUNJARO) I Explain This with Robin Riddle, FNP-C
▶︎